Filter articles using the following links

GenSight Biologics Reports Interim Financial Results for the First Half of 2019 and Provides Operational Update

GenSight Biologics completes enrollment of GS010 REFLECT Phase III trial in the treatment of Leber Hereditary Optic Neuropathy ahead of schedule

UMDF Mitochondrial Medicine 2019, Washington DC, US

GenSight Biologics expands its Board of Directors with the appointments of Maritza McIntyre and Sofinnova Partners

GenSight Biologics announces presentation of results from the REVERSE Phase III trial of GS010 at the 14th meeting of the European Neuro-Ophthalmology Society (EUNOS)

14th Meeting of EUNOS, Porto, Portugal

2019 SOE Congress, European Society of Ophthalmology, Nice, France

BIO International Convention, Philadelphia, PA (US)

Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude

GenSight Biologics to Host KOL Breakfast on May 23, 2019 in New York